

Markus S Anker

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/10128066/publications.pdf>

Version: 2024-02-01

63
papers

2,929
citations

279701

23
h-index

182361

51
g-index

63
all docs

63
docs citations

63
times ranked

4042
citing authors

#	ARTICLE	IF	CITATIONS
1	Long-term prognostic value of vasodilator stress cardiac magnetic resonance in patients with atrial fibrillation. ESC Heart Failure, 2022, 9, 110-121.	1.4	2
2	Assessment of coronary artery disease during hospitalization for cancer treatment. Clinical Research in Cardiology, 2021, 110, 200-210.	1.5	14
3	Advanced cancer is also a heart failure syndrome: a hypothesis. European Journal of Heart Failure, 2021, 23, 140-144.	2.9	20
4	Ventricular tachycardia, premature ventricular contractions, and mortality in unselected patients with lung, colon, or pancreatic cancer: a prospective study. European Journal of Heart Failure, 2021, 23, 145-153.	2.9	18
5	Hypertension delays viral clearance and exacerbates airway hyperinflammation in patients with COVID-19. Nature Biotechnology, 2021, 39, 705-716.	9.4	129
6	Cardiac events associated with immune checkpoint inhibitor therapy: the devil is in the detail. European Heart Journal, 2021, 42, 1637-1637.	1.0	3
7	ECG Scoring for the Evaluation of Therapy-Naïve Cancer Patients to Predict Cardiotoxicity. Cancers, 2021, 13, 1197.	1.7	4
8	Advanced cancer is also a heart failure syndrome: a hypothesis. Journal of Cachexia, Sarcopenia and Muscle, 2021, 12, 533-537.	2.9	13
9	Spontaneous Non-Sustained Ventricular Tachycardia and Premature Ventricular Contractions and Their Prognostic Relevance in Patients with Cancer in Routine Care. Cancers, 2021, 13, 2303.	1.7	5
10	Reply to "Heart failure with preserved ejection fraction and COVID-19: which comes first, the chicken or the egg?". European Journal of Heart Failure, 2021, 23, 2092-2093.	2.9	0
11	Heart failure with preserved ejection fraction according to the HFA-PEFF score in COVID-19 patients: clinical correlates and echocardiographic findings. European Journal of Heart Failure, 2021, 23, 1891-1902.	2.9	21
12	Weight loss, malnutrition, and cachexia in COVID-19: facts and numbers. Journal of Cachexia, Sarcopenia and Muscle, 2021, 12, 9-13.	2.9	90
13	Sarcopenia and cachexia in chronic diseases: from mechanisms to treatment. Polish Archives of Internal Medicine, 2021, , .	0.3	3
14	A year in heart failure: an update of recent findings. ESC Heart Failure, 2021, 8, 4370-4393.	1.4	28
15	JCSM: growing together with cachexia and sarcopenia research. Journal of Cachexia, Sarcopenia and Muscle, 2021, 12, 1359-1367.	2.9	3
16	What do patients with heart failure die from? A single assassin or a conspiracy?. European Journal of Heart Failure, 2020, 22, 26-28.	2.9	11
17	Clinical problems of patients with cachexia due to chronic illness: a congress report. ESC Heart Failure, 2020, 7, 3414-3420.	1.4	2
18	Role of serum biomarkers in cancer patients receiving cardiotoxic cancer therapies: a position statement from the Cardio-Oncology Study Group of the Heart Failure Association and the Cardio-Oncology Council of the European Society of Cardiology. European Journal of Heart Failure, 2020, 22, 1966-1983.	2.9	184

#	ARTICLE	IF	CITATIONS
19	ESC Heart Failure increases its impact factor. ESC Heart Failure, 2020, 7, 3421-3426.	1.4	1
20	Heart failure in the last year: progress and perspective. ESC Heart Failure, 2020, 7, 3505-3530.	1.4	52
21	Muscle wasting as an independent predictor of survival in patients with chronic heart failure. Journal of Cachexia, Sarcopenia and Muscle, 2020, 11, 1242-1249.	2.9	76
22	Liraglutide for Adolescents with Obesity. New England Journal of Medicine, 2020, 383, 1192-1194.	13.9	3
23	Muscle Wasting and Sarcopenia in Heart Failure – The Current State of Science. International Journal of Molecular Sciences, 2020, 21, 6549.	1.8	62
24	The heart failure specialists of tomorrow: a network for young cardiovascular scientists and clinicians. ESC Heart Failure, 2020, 7, 873-877.	1.4	2
25	Baseline cardiovascular risk assessment in cancer patients scheduled to receive cardiotoxic cancer therapies: a position statement and new risk assessment tools from the Cardio-Oncology Study Group of the Heart Failure Association of the European Society of Cardiology in collaboration with the International Cardio-Oncology Society. European Journal of Heart Failure, 2020.	2.9	364
26	Increased resting heart rate and prognosis in treatment-naïve unselected cancer patients: results from a prospective observational study. European Journal of Heart Failure, 2020, 22, 1230-1238.	2.9	23
27	Roxadustat for Anemia in Patients with Chronic Kidney Disease. New England Journal of Medicine, 2020, 383, e3.	13.9	10
28	Role of cardiovascular imaging in cancer patients receiving cardiotoxic therapies: a position statement on behalf of the Heart Failure Association (HFA), the European Association of Cardiovascular Imaging (EACVI) and the Cardio-Oncology Council of the European Society of Cardiology (ESC). European Journal of Heart Failure, 2020, 22, 1504-1524.	2.9	234
29	Blocking myostatin: muscle mass equals muscle strength?. Journal of Cachexia, Sarcopenia and Muscle, 2020, 11, 1396-1398.	2.9	7
30	The 10th year of the Journal of Cachexia, Sarcopenia and Muscle. Journal of Cachexia, Sarcopenia and Muscle, 2020, 11, 1390-1395.	2.9	2
31	Evidence for a cardiac metabolic switch in patients with Hodgkin's lymphoma. ESC Heart Failure, 2019, 6, 824-829.	1.4	14
32	Clinical practice update on heart failure 2019: pharmacotherapy, procedures, devices and patient management. An expert consensus meeting report of the Heart Failure Association of the European Society of Cardiology. European Journal of Heart Failure, 2019, 21, 1169-1186.	2.9	490
33	Orphan disease status of cancer cachexia in the USA and in the European Union: a systematic review. Journal of Cachexia, Sarcopenia and Muscle, 2019, 10, 22-34.	2.9	113
34	The difference in referencing in Web of Science, Scopus, and Google Scholar. ESC Heart Failure, 2019, 6, 1291-1312.	1.4	25
35	Recent advances in cardio-oncology: a report from the Heart Failure Association 2019 and World Congress on Acute Heart Failure 2019™. ESC Heart Failure, 2019, 6, 1140-1148.	1.4	34
36	ESC Heart Failure receives its first impact factor. European Journal of Heart Failure, 2019, 21, 1490.	2.9	1

#	ARTICLE	IF	CITATIONS
37	Cardiac cachexia. <i>European Heart Journal Supplements</i> , 2019, 21, L24-L27.	0.0	19
38	Cardiac cachexia: the mandate to increase clinician awareness. <i>Current Opinion in Supportive and Palliative Care</i> , 2019, 13, 298-304.	0.5	11
39	The Journal of Cachexia, Sarcopenia and Muscle stays the frontâ€runner in geriatrics and gerontology. <i>Journal of Cachexia, Sarcopenia and Muscle</i> , 2019, 10, 1151.	2.9	3
40	Novel biomarkers in heart failure and cardio-oncology. <i>Kardiologia Polska</i> , 2019, 77, 329-330.	0.3	2
41	Cancer diagnosis in patients with heart failure: epidemiology, clinical implications and gaps in knowledge. <i>European Journal of Heart Failure</i> , 2018, 20, 879-887.	2.9	138
42	Updates in heart failure: what last year brought to us. <i>ESC Heart Failure</i> , 2018, 5, 989-1007.	1.4	10
43	Modernâ€day cardioâ€oncology: a report from the â€Heart Failure and World Congress on Acute Heart Failure 2018â€™. <i>ESC Heart Failure</i> , 2018, 5, 1083-1091.	1.4	23
44	Metabolic disorders in heart failure and cancer. <i>ESC Heart Failure</i> , 2018, 5, 1092-1098.	1.4	34
45	The new Heart Failure Association journal â€ ESC Heart Failure. <i>European Journal of Heart Failure</i> , 2018, 20, 1657-1663.	2.9	0
46	Smoking and Other Risk Factors in Type 2 Diabetes. <i>New England Journal of Medicine</i> , 2018, 379, 2572-2575.	13.9	3
47	Time to jump on the bandwagon: the Journal of Cachexia, Sarcopenia and Muscle in 2018. <i>Journal of Cachexia, Sarcopenia and Muscle</i> , 2018, 9, 793-801.	2.9	5
48	Cancer and heart failureâ€more than meets the eye: common risk factors and coâ€morbidity. <i>European Journal of Heart Failure</i> , 2018, 20, 1382-1384.	2.9	34
49	The importance of registries in today's heart failure therapies. <i>Kardiologia Polska</i> , 2018, 76, 1029-1030.	0.3	0
50	Systolicâ€diastolic hypertension versus isolated systolic hypertension and incident heart failure in older adults: Insights from the Cardiovascular Health Study. <i>International Journal of Cardiology</i> , 2017, 235, 11-16.	0.8	26
51	Treatment of systolic hypertension and low diastolic blood pressure in older adults: How low is too low?!. <i>International Journal of Cardiology</i> , 2017, 242, 21.	0.8	1
52	Isolated diastolic hypertension and incident heart failure in community-dwelling older adults: Insights from the Cardiovascular Health Study. <i>International Journal of Cardiology</i> , 2017, 238, 140-143.	0.8	19
53	Sarcopenia, cachexia, and muscle performance in heart failure: Review update 2016. <i>International Journal of Cardiology</i> , 2017, 238, 5-11.	0.8	68
54	Lack of evidence of lower 30-day all-cause readmission in Medicare beneficiaries with heart failure and reduced ejection fraction discharged on spironolactone. <i>International Journal of Cardiology</i> , 2017, 227, 462-466.	0.8	16

#	ARTICLE	IF	CITATIONS
55	Resting heart rate is an independent predictor of death in patients with colorectal, pancreatic, and non-small cell lung cancer: results of a prospective cardiovascular long-term study. <i>European Journal of Heart Failure</i> , 2016, 18, 1524-1534.	2.9	70
56	Prevalence and clinical impact of cachexia in chronic illness in Europe, USA, and Japan: facts and numbers update 2016. <i>Journal of Cachexia, Sarcopenia and Muscle</i> , 2016, 7, 507-509.	2.9	210
57	Advances in cachexia and sarcopenia research in the heart failure context. <i>Journal of Cardiovascular Medicine</i> , 2016, 17, 860-862.	0.6	6
58	TWIST1 regulates the activity of ubiquitin proteasome system via the miR-199/214 cluster in human end-stage dilated cardiomyopathy. <i>International Journal of Cardiology</i> , 2013, 168, 1447-1452.	0.8	47
59	Highlights of the mechanistic and therapeutic cachexia and sarcopenia research 2010 to 2012 and their relevance for cardiology. <i>International Journal of Cardiology</i> , 2013, 162, 73-76.	0.8	23
60	State of the art paper Highlights of mechanistic and therapeutic cachexia and sarcopenia research 2010 to 2012 and their relevance for cardiology. <i>Archives of Medical Science</i> , 2013, 1, 166-171.	0.4	25
61	Anemia in chronic heart failure: Can we treat? What to treat?. <i>Heart Failure Reviews</i> , 2012, 17, 203-210.	1.7	33
62	Management of Chronic Cardiorenal Syndrome. <i>Contributions To Nephrology</i> , 2010, 165, 129-139.	1.1	7
63	Biomarkers for Chronic Heart Failure. <i>Herz</i> , 2009, 34, 589-593.	0.4	33